These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26823290)

  • 1. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.
    Dobson L; Träger U; Farmer R; Hayardeny L; Loupe P; Hayden MR; Tabrizi SJ
    J Neurochem; 2016 Jun; 137(5):782-94. PubMed ID: 26823290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?
    Björkqvist M
    J Neurochem; 2016 Jun; 137(5):670-2. PubMed ID: 27059524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.
    Engel S; Jolivel V; Kraus SH; Zayoud M; Rosenfeld K; Tumani H; Furlan R; Kurschus FC; Waisman A; Luessi F
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33203651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.
    Träger U; Andre R; Lahiri N; Magnusson-Lind A; Weiss A; Grueninger S; McKinnon C; Sirinathsinghji E; Kahlon S; Pfister EL; Moser R; Hummerich H; Antoniou M; Bates GP; Luthi-Carter R; Lowdell MW; Björkqvist M; Ostroff GR; Aronin N; Tabrizi SJ
    Brain; 2014 Mar; 137(Pt 3):819-33. PubMed ID: 24459107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.
    Garcia-Miralles M; Yusof NABM; Tan JY; Radulescu CI; Sidik H; Tan LJ; Belinson H; Zach N; Hayden MR; Pouladi MA
    Mol Neurobiol; 2019 Jun; 56(6):4464-4478. PubMed ID: 30334188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
    Schulze-Topphoff U; Shetty A; Varrin-Doyer M; Molnarfi N; Sagan SA; Sobel RA; Nelson PA; Zamvil SS
    PLoS One; 2012; 7(3):e33797. PubMed ID: 22479444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
    Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
    Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.
    Miller JR; Lo KK; Andre R; Hensman Moss DJ; Träger U; Stone TC; Jones L; Holmans P; Plagnol V; Tabrizi SJ
    Hum Mol Genet; 2016 Jul; 25(14):2893-2904. PubMed ID: 27170315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.
    Garcia-Miralles M; Hong X; Tan LJ; Caron NS; Huang Y; To XV; Lin RY; Franciosi S; Papapetropoulos S; Hayardeny L; Hayden MR; Chuang KH; Pouladi MA
    Sci Rep; 2016 Aug; 6():31652. PubMed ID: 27528441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
    Lourenço EV; Wong M; Hahn BH; Palma-Diaz MF; Skaggs BJ
    Arthritis Rheumatol; 2014 Mar; 66(3):674-85. PubMed ID: 24574228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.
    Chang KH; Wu YR; Chen YC; Chen CM
    Brain Behav Immun; 2015 Feb; 44():121-7. PubMed ID: 25266150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.
    Träger U; Andre R; Magnusson-Lind A; Miller JR; Connolly C; Weiss A; Grueninger S; Silajdžić E; Smith DL; Leavitt BR; Bates GP; Björkqvist M; Tabrizi SJ
    Neurobiol Dis; 2015 Jan; 73():388-98. PubMed ID: 25447230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease.
    Du G; Dong W; Yang Q; Yu X; Ma J; Gu W; Huang Y
    Front Immunol; 2020; 11():603594. PubMed ID: 33679692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laquinimod treatment in the R6/2 mouse model.
    Ellrichmann G; Blusch A; Fatoba O; Brunner J; Reick C; Hayardeny L; Hayden M; Sehr D; Winklhofer KF; Saft C; Gold R
    Sci Rep; 2017 Jul; 7(1):4947. PubMed ID: 28694434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease.
    Hensman Moss DJ; Flower MD; Lo KK; Miller JR; van Ommen GB; 't Hoen PA; Stone TC; Guinee A; Langbehn DR; Jones L; Plagnol V; van Roon-Mom WM; Holmans P; Tabrizi SJ
    Sci Rep; 2017 Mar; 7():44849. PubMed ID: 28322270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
    Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
    Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
    Mishra MK; Wang J; Silva C; Mack M; Yong VW
    Am J Pathol; 2012 Aug; 181(2):642-51. PubMed ID: 22749771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.
    Ehrnhoefer DE; Caron NS; Deng Y; Qiu X; Tsang M; Hayden MR
    Exp Neurol; 2016 Sep; 283(Pt A):121-8. PubMed ID: 27296315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease.
    Pido-Lopez J; Andre R; Benjamin AC; Ali N; Farag S; Tabrizi SJ; Bates GP
    Sci Rep; 2018 Jul; 8(1):11447. PubMed ID: 30061661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.
    Weiss A; Träger U; Wild EJ; Grueninger S; Farmer R; Landles C; Scahill RI; Lahiri N; Haider S; Macdonald D; Frost C; Bates GP; Bilbe G; Kuhn R; Andre R; Tabrizi SJ
    J Clin Invest; 2012 Oct; 122(10):3731-6. PubMed ID: 22996692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.